Pfizer launches biosimilars to Roche's 'big three' cancer dr...

Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.

GSK has no immediate plans to spin off Pfizer joint venture

GlaxoSmithKline has made no plans to spin off or float its consumer healthcare joint venture with Pfizer, according to a top company executive.

Pfizer/Merck KGaA's Bavencio set for bladder cancer advantag...

Pfizer and German Merck can breathe a sigh of relief after a phase 3 trial confirmed that their immunotherapy Bavencio produces a survival benefit in bladder cancer, when used as a maintena

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

Xtandi catches up with Erleada in castration-sensitive prost...

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Pfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK cancer landscape.